viral hepatitis; liver disease; liver cancer; vaccine; therapeutic strategy; virus-host interactions

Functional genomics of viral hepatitis and liver disease

Laboratoires d'excellence (LABX)

Laboratoires d'excellence in Idex

Informations générales

Référence projet : 10-LABX-0028
Etablissement Coordinateur : Université de Strasbourg
Région du projet : Grand Est
Discipline : 5 - Bio Med

Aide de l'ANR 3 000 000 euros
Investissement couvrant la période de avril 2011 à décembre 2019

Résumé de soumission


Chronic viral hepatitis is a major cause of chronic liver disease and hepatocellular carcinoma (HCC), the second leading cause of cancer death. A protective hepatitis C vaccine and curative therapies for chronic hepatitis B are absent. Furthermore, there are no efficient strategies to prevent virus-induced HCC development once cirrhosis is established while treatment options for advanced liver disease remain unsatisfactory. Addressing these major unmet medical needs, HepSYS has developed novel state-of-the-art technologies to uncover the cell circuits that drive virus-induced liver disease and cancer for the development of novel biomarkers and therapies for liver disease and HCC. HepSYS has developed novel cell culture and animal models to uncover innovative approaches for HBV cure and applies its unique liver chimeric mouse models and expertise in B cell immunology to contribute to HCV vaccine design. The transformative discoveries place HepSYS as a world leader at the forefront of the field. These include the molecular and translational analysis of virus-host interactions and liver disease and cancer, the study of virus-host interactions and lipid metabolism, the development of humanized animal models for the study of disease biology and virus-induced cancer as well as clinical trials for prevention and treatment of virus-induced liver disease and cancer. In 2016 HepSYS scientists have published 66 articles in high-impact journals such as The Lancet Infectious Diseases, Cancer Cell, PNAS, Cell Reports, Scientific Reports, Gastroenterology, Gut, Hepatology with a total impact factor of 384 (IF original 258.5/IF review 125.5). By levering more than 30 M€ external funding including 11.5 M€ direct funding, over 4 M€ in networks and 1.7 M€ direct funding secured in 2016, and by building several networks of excellence, HepSYS continues to make a marked impact on its host institution.


L'auteur de ce résumé est le coordinateur du projet, qui est responsable du contenu de ce résumé. L'ANR décline par conséquent toute responsabilité quant à son contenu.

Liens utiles